6WKM
Fab Fragment of Anti-human LAG3 antibody (22D2)
6WKM の概要
エントリーDOI | 10.2210/pdb6wkm/pdb |
分子名称 | 22D2 Fab Heavy Chain, 22D2 Fab Light Chain (3 entities in total) |
機能のキーワード | anti human lag3, immune system |
由来する生物種 | Mus musculus 詳細 |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 48977.37 |
構造登録者 | |
主引用文献 | Mishra, A.K.,Shahid, S.,Karade, S.S.,Agnihotri, P.,Kolesnikov, A.,Hasan, S.S.,Mariuzza, R.A. CryoEM structure of a therapeutic antibody (favezelimab) bound to human LAG3 determined using a bivalent Fab as fiducial marker. Structure, 2023 Cited by PubMed Abstract: Lymphocyte activation gene 3 protein (LAG3) is an inhibitory receptor that is upregulated on exhausted T cells in tumors. LAG3 is a major target for cancer immunotherapy with many anti-LAG3 antibodies in clinical trials. However, there is no structural information on the epitopes recognized by these antibodies. We determined the single-particle cryoEM structure of a therapeutic antibody (favezelimab) bound to LAG3 to 3.5 Å resolution, revealing that favezelimab targets the LAG3-binding site for MHC class II, its canonical ligand. The small size of the complex between the conventional (monovalent) Fab of favezelimab and LAG3 (∼100 kDa) presented a challenge for cryoEM. Accordingly, we engineered a bivalent version of Fab favezelimab that doubled the size of the Fab-LAG3 complex and conferred a highly identifiable shape to the complex that facilitated particle selection and orientation for image processing. This study establishes bivalent Fabs as new fiducial markers for cryoEM analysis of small proteins. PubMed: 37619561DOI: 10.1016/j.str.2023.07.013 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.1 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード